Literature DB >> 22810303

Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial.

Robert K Dyer1, Martin A Weinstock, Tobias S D Cohen, Amilcar E Rizzo, Stephen F Bingham.   

Abstract

Basal cell carcinoma (BCC) is the most common cancer in the United States today, and patients who have had one are likely to have multiple carcinomas over time. Predictors of new BCCs on the face and ears among those at very high risk have not been studied in detail. We sought to do so prospectively in the context of a 6-year trial. We found that the number of BCCs in the prior 5 years was the most important predictor. Age, sun sensitivity, occupational sun exposure before the age of 30 years (but not afterward), lower educational level, history of eczema, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in the week, but not the 6 months, before enrollment were also independent predictors, but sunburns, baseline sun exposure, and other sun-protective measures, other skin cancers, and actinic keratoses were not. None of the eczema patients had a history of topical calcineurin use. The cumulative risk of BCC was 55% at 5 years. These findings document the key risk factors in this very high-risk population, suggesting that the history of eczema may increase the risk in those at high risk and that early sun exposure is important even in this group, and underscoring the need for chemopreventive strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22810303     DOI: 10.1038/jid.2012.227

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  The potential for malignancy from atopic disorders and allergic inflammation: A systematic review and meta-analysis.

Authors:  Amanda B Muir; Kelly A Whelan; Michael K Dougherty; Bailey Aaron; Brianna Navarre; Seema S Aceves; Evan S Dellon; Elizabeth T Jensen
Journal:  Clin Exp Allergy       Date:  2019-12-20       Impact factor: 5.018

2.  Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.

Authors:  Myrna L Ortiz; Vinit Kumar; Anna Martner; Sridevi Mony; Laxminarasimha Donthireddy; Thomas Condamine; John Seykora; Stella C Knight; George Malietzis; Gui Han Lee; Morgan Moorghen; Brianna Lenox; Noreen Luetteke; Esteban Celis; Dmitry Gabrilovich
Journal:  J Exp Med       Date:  2015-02-09       Impact factor: 14.307

3.  Atopic Dermatitis and Skin Cancer Risk: A Systematic Review.

Authors:  Yun Zhu; Hongmei Wang; Juan He; Luhui Yang; Xiaoyan Zhou; Zhe Li; Huiling Zhou; Huadi Zhao; Yuye Li
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-17

4.  Assessing individual patients' knowledge of benign versus malignant skin lesions in the dermatology clinic population.

Authors:  Kristin Lee; Ngoc Nguyen; Meghan Fuzzell; Eleanor Tung-Hahn; Jeave Reserva; Neelam Balasubramanian; Rebecca Tung; Murad Alam; Thomas Stasko
Journal:  Int J Womens Dermatol       Date:  2022-07-25

5.  Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors.

Authors:  Effat Khodaeiani; Ashraf Fakhrjou; Mehdi Amirnia; Shahla Babaei-Nezhad; Farshid Taghvamanesh; Elham Razzagh-Karimi; Hossein Alikhah
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

6.  Filaggrin genotype does not determine the skin's threshold to UV-induced erythema.

Authors:  Deborah Forbes; Leona Johnston; June Gardner; Stephanie F MacCallum; Linda E Campbell; Albena T Dinkova-Kostova; W H Irwin McLean; Sally H Ibbotson; Robert S Dawe; Sara J Brown
Journal:  J Allergy Clin Immunol       Date:  2016-01-29       Impact factor: 10.793

Review 7.  [What's new in clinical dermatology?].

Authors:  M Janier
Journal:  Ann Dermatol Venereol       Date:  2013-11       Impact factor: 0.777

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.